Laura T. Grip

TL;DR: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

TL;DR: Cardiovascular drugs with narrow therapeutic indexes have demonstrated large increases in concentrations when coadministered with potent P-gp inhibitors, thus increasing the risk for drug toxicity and dose adjustment or use of alternative agents should be considered when strong P- gp-mediated drug-drug interactions are present.

TL;DR: In a contemporary AF population, LA structure and function were increasingly abnormal with a greater electrical burden of AF and higher stroke risk estimated by the CHADS2 score, suggesting that the assessment of LA function may add important incremental information in the evaluation of AF patients.

TL;DR: The results from this first trial of INO-1001 in STEMI support future investigation of INo-1001 as a novel treatment for reperfusion injury.

TL;DR: The ENGAGE AF-TIMI 48 transition plan protected patients from an excess of thrombotic and bleeding events and should be helpful in clinical practice when patients are transitioned between oral anticoagulants.